The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
Has known secondary hypertension or serum potassium more than 5 mmol/L
Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m²
Alnylam Pharmaceuticals
Lead sponsor
Hoffmann-La Roche
Collaborator